Can we infer from the hesitation in your posts, that you are still concerned about the effectiveness of Squalamine because the results of the lower dose patients were not announced? Do you suspect that if in fact the results from lower doses are not as good, that means Squalamine's overall affectiveness may be not as great? Or are you just knitpicking at this point?
Market Data 
Markets 
AI
